Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Oct-Dec;13(4):185-192.
doi: 10.14797/mdcj-13-4-185.

Prevention of Cardiovascular Disease in Women

Affiliations
Review

Prevention of Cardiovascular Disease in Women

Anum Saeed et al. Methodist Debakey Cardiovasc J. 2017 Oct-Dec.

Abstract

Cardiovascular diseases are the leading cause of morbidity and mortality among women worldwide. The pathophysiological basis of cardiovascular health among men and women is not identical. This leads to variable cardiovascular responses to stimulus and presentation of cardiovascular disease symptoms, both of which can have a direct effect on treatment outcomes. Traditionally, the enrollment of women in clinical trials has been minimal, resulting in a lack of gender-specific analysis of clinical trial data and, therefore, the absence of concrete risk factor assessment among women. However, scientific progress in the past decade has identified a spectrum of risk factors for cardiovascular diseases that may be specific to women. These risk factors, which may include menopause, hypertensive disease of pregnancy, and depression, confer additional risk in women besides the traditional risk factors. The current state of knowledge and awareness about these risk factors is suboptimal at this time. Therefore, although the treatment of cardiovascular diseases is similar in both genders, appropriate risk stratification may be limited in women compared to men. The purpose of this review is to describe the recent trends in identifying female-specific risk factors for cardiovascular diseases, their utility in risk stratification, and current pharmacological options for women with regard to cardiovascular disease prevention.

Keywords: cardiovascular disease; cardiovascular risk factors; postmenopausal CVD; women and CVD.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosure: Dr. Nambi receives research funding from Merck through Baylor College of Medicine, served on a regional advisory board for Sanofi-Regeneron, received an honorarium from Siemens Healthcare Diagnostics, and holds a provisional patent entitled “Biomarkers to Improve Prediction of Heart Failure Risk” filed by Baylor College of Medicine and Roche.

References

    1. Benjamin EJ, Blaha MJ, Chiuve SE, . et al. .; American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart Disease and Stroke Statistics-2017 Update: A Report from the American Heart Association. Circulation. 2017. March 7; 135 10: e146– e603. - PMC - PubMed
    1. Gulati M, Shaw LJ, Bairey Merz CN.. Myocardial ischemia in women: lessons from the NHLBI WISE study. Clin Cardiol. 2012. March; 35 3: 141– 8. - PMC - PubMed
    1. von Mering GO, Arant CB, Wessel TR, . et al. Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women: results from the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation. 2004. February 17; 109 6: 722– 5. - PubMed
    1. Reynolds HR, Srichai MB, Iqbal SN, . et al. Mechanisms of myocardial infarction in women without angiographically obstructive coronary artery disease. Circulation. 2011. September 27; 124 13: 1414– 25. - PMC - PubMed
    1. Hochman JS, Tamis JE, Thompson TD, . et al. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. N Engl J Med. 1999. July 22; 341 4: 226– 32. - PubMed